Form DEF 14A ZAI LAB LIMITED For: 28 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zai Lab Ltd (ZLAB)
The Zai Lab share price today is 21.01, view NASDAQ ZLAB stock exchange data. Track the latest Zai Lab share price with real-time updates on ZLAB stock performance including market cap, day range, 52-week range and dividend yield. Access ZLAB charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.37
21.46
52 wk Range
15.96
44.34
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.3721.46
52 wk Range
15.9644.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZLAB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
35.34
Upside
+68.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
- Form 13G Zai Lab Limited For: 6 April
- Investing.com
- Form 144 Zai Lab Ltd For: 6 April
- Investing.com
- Form DEF 14A ZAI LAB LIMITED For: 28 April
- Investing.com
- Form PRE 14A ZAI LAB LIMITED For: 17 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.34
(+68.22% Upside)
Zai Lab Ltd Earnings Call Summary for Q4/2025
- Zai Lab reported Q4 2025 EPS of -$0.05, beating forecast of -$0.37 by 86.49%; revenue rose 17% YoY to $127.6M, slightly above estimates.
- Full-year revenue reached $460.2M, up 15% YoY, driven by strong performance from XACDURO and NUZYRA; cash position stood at $790M at year-end.
- Stock declined 3.3% in premarket to $18.75 despite earnings beat, reflecting broader market concerns and cautious investor sentiment.
- Company projects FY2026 revenue of $525.25M, focusing on expanding oncology and immunology pipeline with key trials planned for 2026 and beyond.
- CEO Du emphasized strategic initiatives' effectiveness; risks include supply chain constraints, generic competition, and China macroeconomic pressures.
Last Updated: 26-02-2026, 07:38 pm
Read Full TranscriptEarnings
Latest Release
26-02-2026
EPS / Forecast
-0.05 / -0.37
Revenue / Forecast
127.6M / 127.09M
Compare ZLAB to Peers and Sector
Metrics to compare | ZLAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZLABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.4x | −3.3x | −0.5x | |
PEG Ratio | −0.35 | −0.19 | 0.00 | |
Price/Book | 3.3x | 6.4x | 2.6x | |
Price / LTM Sales | 5.1x | 14.8x | 3.2x | |
Upside (Analyst Target) | 56.6% | 221.5% | 48.3% | |
Fair Value Upside | Unlock | −7.6% | 5.6% | Unlock |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Zai Lab (ZLAB) Share Price Today?
The Zai Lab share price today is 21.01.
What is the current Zai Lab (ZLAB) share price and day range?
As of 07-05-2026, the Zai Lab share price is 21.01, with a previous close of 20.98. The share price has ranged from 20.37 to 21.46 today, while the 52-week range spans from 15.96 to 44.34.
What Is the Zai Lab Market Cap?
As of today, Zai Lab market cap is 2.36B.
What Is the Zai Lab (ZLAB) Share Price Target?
The average 12-month share price target for Zai Lab is 35.34, with a high estimate of 53 and a low estimate of 24. 11 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +68.22% Upside potential.
What Is Zai Lab's Earnings Per Share (TTM)?
The Zai Lab EPS (TTM) is -1.60.
When Is the Next Zai Lab Earnings Date?
Zai Lab will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is ZLAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Zai Lab Trade On?
Zai Lab is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Zai Lab?
The stock symbol for Zai Lab is "ZLAB."
How Many Times Has Zai Lab Stock Split?
Zai Lab has split 0 times.
How Many Employees Does Zai Lab Have?
Zai Lab has 1784 employees.
What Is the ZLAB Premarket Price?
ZLAB's last pre-market stock price is 20.88. The pre-market share volume is 3,190.00, and the stock has changed by -0.10, or -0.48%.
What Is the ZLAB After Hours Price?
ZLAB's last after hours stock price is 21.18, the stock has changed by 0.17, or 0.81%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.